Open AccessBullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitors: A report of five cases
Author(s) -
Yoshiji Satoshi,
Murakami Takaaki,
Harashima Shinichi,
Ko Rie,
Kashima Riko,
Yabe Daisuke,
Ogura Masahito,
Doi Kentaro,
Inagaki Nobuya
Publication year - 2018
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/jdi.12695
Subject(s) - medicine , bullous pemphigoid , dipeptidyl peptidase 4 , pemphigoid , glycemic , dipeptidyl peptidase , diabetes mellitus , dipeptidyl peptidase 4 inhibitor , population , autoimmune diabetes , dermatology , gastroenterology , type 2 diabetes mellitus , antibody , type 1 diabetes , immunology , type 2 diabetes , endocrinology , biochemistry , chemistry , enzyme , environmental health
Bullous pemphigoid ( BP ) is an autoimmune blistering skin disorder. Recently, BP induced by dipeptidyl peptidase‐4 ( DPP ‐4) inhibitors has been a concern. Although DPP ‐4 inhibitors are commonly used in the Asian population because of their safety and efficacy, BP associated with DPP ‐4 inhibitors is sometimes seen in clinical settings. Here, we report five Japanese cases of BP associated with the agents. In the present cases, BP occurred in older adults using four different DPP ‐4 inhibitors, which showed various clinical manifestations in terms of latency period for BP , sex, glycemic control and diabetes duration. Withdrawal of DPP ‐4 inhibitors was effective in improving BP , and achieved remission even in cases requiring oral steroid administration and intravenous immunoglobulin therapy. Clinicians should note the importance of early diagnosis of this clinical condition and initiate prompt withdrawal of DPP ‐4 inhibitors.